Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2021-04-12 AGM Information
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 98% confidence The document is explicitly titled as a "PRESS RELEASE" announcing that the "NANOBIOTIX COMBINED SHAREHOLDERS MEETING TO BE HELD APRIL 28, 2021". It details the date, time, and method of attendance (web conference) for the meeting, and provides instructions on how shareholders can vote (postal voting or proxy) and submit written questions. This content directly relates to the logistics and preparatory information for an Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-04-12 English
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and explicitly announces the modalities for making preparatory documents available for the "ASSEMBLÉE GÉNÉRALE MIXTE ANNUELLE" (Annual General Meeting) scheduled for April 28, 2021. It details how shareholders can vote (by correspondence or proxy) and submit written questions, noting the meeting will be held behind closed doors due to health measures. This document is not the full AGM presentation (AGM-R) nor the proxy solicitation materials (PSI), but rather an announcement concerning the logistics and availability of documents related to the upcoming AGM. Since it is an announcement about an upcoming shareholder meeting and the associated voting/information process, it strongly relates to the AGM context. However, the core function here is informing about the meeting logistics and document availability, which often falls under general regulatory announcements or specific AGM communication. Given the explicit focus on the Annual General Meeting (AGM) logistics and the availability of preparatory documents, AGM-R is the most specific fit, although it is an announcement *about* the AGM rather than the presentation itself. If the document were purely about soliciting votes, PSI would fit, but this focuses on the meeting mechanics and document access. Since it is a press release detailing the organization of the AGM, AGM-R is the best fit among the specific options, as it pertains directly to the AGM event.
2021-04-12 French
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 99% confidence The document is a press release titled "NANOBIOTIX ANNONCE LE DÉPOT DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2020 ET DU RAPPORT ANNUEL « FORM 20-F »" (NANOBIOTIX ANNOUNCES FILING OF THE 2020 UNIVERSAL REGISTRATION DOCUMENT AND THE ANNUAL REPORT "FORM 20-F"). The text explicitly states that the company has filed its Universal Registration Document with the AMF and its 'Form 20-F' annual report with the SEC. The Form 20-F is the standard annual report filing for foreign private issuers in the US, which corresponds to the definition of a 10-K (Annual Report) for US domestic issuers, although the specific code for the 20-F is often classified under the general Annual Report category (10-K) or sometimes as a Regulatory Filing (RNS) if it's just an announcement. However, since the document explicitly mentions the filing of the 'rapport annuel' (annual report) and the 20-F, and the document length is substantial (6055 chars), it is announcing the release of the full annual reporting package. Given the specific mention of the 'rapport annuel' and the 20-F, the most appropriate classification is 10-K, as it pertains to the official yearly report covering full financial performance, even though this specific document is the announcement of that filing. If the document were extremely short and only pointed to the filing, RPA or RNS would be better, but this press release details what the filing contains (annual financial report, management report, auditor reports). Therefore, 10-K is the best fit for the underlying document being announced.
2021-04-08 French
Annual financial and audit reports / Terms of availability of the annual financial report
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the filing of the company's 2020 Universal Registration Document and 2020 Annual Report on Form 20-F. It does not contain the actual financial statements or the full report itself, but rather informs the public that these documents have been filed with the AMF and SEC and provides links to where they can be accessed. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA). FY 2020
2021-04-08 English
Nanobiotix URD 2020
Annual Report Classification · 100% confidence The document is identified as a 'Universal Registration Document' (Document d'Enregistrement Universel) filed with the French AMF. This type of document is the European equivalent of an Annual Report (10-K), as it contains comprehensive financial statements, management reports, risk factors, and business descriptions for the fiscal year ended December 31, 2020. It is not an announcement of a report, but the report itself. FY 2020
2021-04-07 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly cites French regulatory articles (Code de commerce and Règlement Général de l'AMF) and provides a table detailing the total number of shares and voting rights as of March 31, 2021. This content directly relates to reporting changes in share capital structure and voting rights, which aligns with the definition of a Major Shareholding Notification (MRQ) or a general regulatory filing. Since it is a specific, recurring monthly disclosure about the capital structure and voting rights, it fits best under Major Shareholding Notification (MRQ) as it reports on the total outstanding shares/rights, which is often a prerequisite for threshold monitoring, or potentially a general regulatory filing (RNS). However, given the specific nature of reporting total shares and voting rights monthly, it is a common requirement often grouped with significant ownership changes or capital structure updates. Comparing the options, 'MRQ' (Major Shareholding Notification) is the closest fit for regular updates on the total number of shares/voting rights, although it is not strictly a notification of a *change* by a specific shareholder, but rather a mandatory disclosure of the total base. Since it is a mandatory regulatory disclosure that doesn't fit perfectly into other specific categories like Dividends (DIV) or Share Issue (SHA), and it is a formal announcement, RNS (Regulatory Filings) is a strong fallback. However, in many databases, these specific capital structure disclosures are categorized under share/capital related events. Given the explicit focus on the total number of shares and voting rights, which is a key metric for major shareholding thresholds, MRQ is plausible. Let's re-evaluate against the definitions. It is not a Director's Dealing (DIRS), nor a Share Issue (SHA) or Transaction in Own Shares (POS). It is a mandatory disclosure of the capital base. In the context of French filings, this is often a specific type of capital disclosure. Since it is a formal, periodic regulatory announcement, RNS is the safest general classification if MRQ is too specific to threshold breaches. Given the options, and the fact that it is a formal, periodic regulatory announcement required by the AMF, RNS (Regulatory Filings) is the most appropriate general category for this type of mandatory, non-financial report announcement.
2021-04-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.